Navigation Links
Elekta Announces Clinical Start-up of Elekta Synergy(R) S at UPMC

PITTSBURGH and ATLANTA, Jan. 10 /PRNewswire/ -- Treatments have commenced on the new Elekta Synergy(R) S at University of Pittsburgh Medical Center (UPMC). UPMC is a world-leading provider of intra- and extracranial stereotactic radiosurgery.

The clinical start of treatments began October 30, 2007 with a colon cancer treatment followed by a lung patient. Since then, the vast majority of patients treated with Elekta Synergy S are spine stereotactic radiosurgery (SRS) patients, most of which are treated in a single session.

Elekta Synergy S is a state-of-the-art digital linear accelerator with ultra-precise patient alignment that uses Elekta's advanced X-ray Volume Imaging (XVI) to acquire ultra low dose 3D cone beam CT volumetric images with the patient in the treatment position for accurate patient alignment. The system then delivers higher, more conformal doses of radiation to the target due to the unique MLC design of Elekta Synergy S, called Beam Modulator(TM). The Beam Modulator was designed for single session SRS, which results in fewer clinic visits for the patient, as well as faster, more efficient treatment times.

"Elekta Synergy S is a very good, very reliable machine," says M. Saiful Huq, Ph.D., FAAPM, FinstP, professor and director of Medical Physics, Department of Radiation Oncology at UPMC Cancer Centers. "With the Elekta Volume View(TM) cone beam CT, we can localize treatment directly to the tumor and spare surrounding healthy tissue. And the robotic HexaPOD(TM) tabletop allows six degrees of correction in rotational or translational errors for extreme accuracy."

With these capabilities, Elekta Synergy S provides a powerful combination of software-driven, image-guided accuracy and highly conformal beam shaping - two critical requirements for maximizing precision and improving patient outcomes in stereotactic treatment.

UPMC partners with Elekta to develop new technologies

UPMC and Elekta have worked together for many years. "We have a strong Elekta presence at UPMC Cancer Centers," says Dr. Huq. "Historically, a great deal of Leksell Gamma Knife(R) development has taken place here, as well as collaboration on other Elekta technology. So Elekta Synergy S was a natural progression for us."

With the addition of Elekta Synergy S to its Leksell Gamma Knife(R) Perfexion(TM) and Leksell Gamma Knife(R) 4C capabilities, the Center for Image Guided Neurosurgery at UPMC has been designated an Elekta Stereotactic Center of Excellence. "We treat one of the largest patient volumes in the world," says Dr. Huq, "and Elekta Synergy S will be a great benefit to our patients."

About Elekta

Elekta is an international medical technology group, providing oncologists, radiation therapists, neurosurgeons and many other medical specialists with state of the art tools to fight serious disease.

Elekta provides advanced clinical solutions, comprehensive management and information systems as well as services for improved cancer care and management of brain disorders.

Elekta's systems and solutions are used in over 4,500 hospitals around the world. Clinical and information management solutions include, among others, Leksell Gamma Knife(R) for non-invasive treatment of brain disorders, Elekta Axesse(TM) and Elekta Synergy(R) for stereotactic and image guided radiation therapy and radiosurgery as well as the MOSAIQ(TM) suite of software for image-enabled EMR and efficient management of clinical and patient data.

With over 2,000 employees globally, the corporate headquarter is located in Stockholm, Sweden and the company is listed on the Nordic Exchange under the ticker EKTAb. More information about Elekta can be found at

About UPMC Cancer Centers

UPMC Cancer Centers offers cancer patients exceptional care and innovative treatments close to home. Working in tandem with the University of Pittsburgh Cancer Institute (UPCI), western Pennsylvania's only National Cancer Institute-designated Comprehensive Cancer Center, UPMC Cancer Centers provides the latest advances in cancer prevention, detection, diagnosis, and treatment at more than 40 community-based locations throughout the region. UPCI comprises the academic and research activities for cancer at the University of Pittsburgh and the University of Pittsburgh Medical Center.

Disclosure Statement

UPMC and Elekta have partnered in the assessment and use of a variety of technologies over the last 25 years, including stereotactic guiding technologies, robotic surgical microscopes, magnetoencephalography, linear accelerator radiation systems and Gamma Knife(R) radiosurgery. Certain doctors at UPMC serve on an advisory panel and act as paid consultants to Elekta.

SOURCE Elekta, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
2. Elekta Demonstrates Commitment to Stereotactic Innovation at EANS
3. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
4. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
5. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
6. Elekta Brings Intelligent Ways to Manage Motion During Cancer Treatment to ESTRO
7. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
8. Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007
9. Elekta Announces Elekta Infinity - a New System for Faster and More Precise Treatment of Cancer Tumors
10. Beaumont Hospital, Royal Oak Treats Its First Patients With Elekta Axesse
11. Elekta Showcases Stereotactic Systems for Cancer Care at Astro 2007
Post Your Comments:
(Date:11/30/2015)... 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the ... C.W. Wong to its Board of Directors to replace ... with a wealth of experience as co-founder of Resverlogix, with ... --> --> Dr. Wong remarked, ... of directors. Zenith,s long standing expertise in epigenetics and the ...
(Date:11/30/2015)... -- TapImmune, Inc. (TPIV), a clinical-stage ... and gene-based immunotherapeutics and vaccines for the treatment of ... presenting at the 8 th Annual LD Micro ... PT. Dr. John N. Bonfiglio a TapImmune ... presentation and will join TapImmune management in meeting with ...
(Date:11/30/2015)... 2015  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW ... therapies for solid tumor cancers, announced today that the ... and the Company welcomes Neil Woodford,s call ... anonymous internet report on NW Bio.  The Company,s Board ... Powers stated, "We agree with Mr. Woodford that, ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, ... applied spectroscopy, covers a wide range of applications such as, but not limited ...
Breaking Biology Technology:
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
Breaking Biology News(10 mins):